221 results match your criteria: "Deeley Research Centre[Affiliation]"

Intermittent Fasting in Cancer: a Role in Survivorship?

Curr Nutr Rep

September 2022

Medical Oncology, BC Cancer - Victoria, Victoria, Canada.

Purpose Of Review: To discuss the historical development of intermittent fasting, its potential underlying mechanisms, and the state of clinical trials, and to reflect on considerations for practice and future recommendations.

Recent Findings: Preclinical studies consistently show the robust disease-modifying efficacy of intermittent fasting in various metabolic diseases which may hold implications for cancer prevention and survivorship. Twenty-one clinical trials have or are being conducted on fasting in cancer, utilizing various fasting regimens across different tumor types as a stand-alone intervention or in adjunct to anticancer treatment, with heterogenous outcome variables.

View Article and Find Full Text PDF

Building the Canadian Bladder Cancer Research Network (CBCRN): Progress during a pandemic.

Can Urol Assoc J

June 2022

Department of Surgery (Urology) and Surgical Oncology, Princess Margaret Cancer Centre and the University Health Network, University of Toronto, Toronto, ON, Canada.

View Article and Find Full Text PDF
Article Synopsis
  • Scientists are exploring how immune cells can fight cancer and why they don't always succeed, using ideas from ecology about predators and prey.
  • Understanding the "tumour microenvironment," where cancer cells live, is super important for improving treatments.
  • They want to find new ways to combine therapies and target cancer better by using what they’ve learned about how immune cells behave like predators against cancer cells.
View Article and Find Full Text PDF

The Availability of Human Biospecimens to Support Biomarker Research.

Biomark Insights

April 2022

Biobanking and Biospecimen Research Services, Deeley Research Centre, BC Cancer, Victoria, BC, Canada.

Preserved biospecimens held in biobank inventories and clinical archives are important resources for biomarker research. Recent advances in technologies have led to an increase in use of clinical archives in particular, in order to study retrospective cohorts and to generate data relevant to tissue biomarkers. This raises the question of whether the current sizes of biobank inventories are appropriate to meet the demands of biomarker research.

View Article and Find Full Text PDF

Breaching B cell tolerance in the tumor microenvironment.

Cancer Cell

April 2022

Deeley Research Centre, BC Cancer, Victoria, BC V8R 6V5, Canada; Department of Medical Genetics, University of British Columbia, Vancouver, BC V6T 1Z3, Canada; Department of Biochemistry and Microbiology, University of Victoria, Victoria, BC V8P 3E6, Canada. Electronic address:

The immune system employs complex tolerance mechanisms in order to avoid harmful autoimmunity, yet autoantibodies are frequently observed in cancer. In a paper in Cell, Mazor et al. report that autoantibodies produced by tumor-infiltrating B cells in human ovarian cancer frequently recognize the self-protein matrix metalloproteinase 14 (MMP14) through two distinct mechanisms of tolerance disruption.

View Article and Find Full Text PDF

Although immunotherapy research to date has focused largely on T cells, there is mounting evidence that tumour-infiltrating B cells and plasma cells (collectively referred to as tumour-infiltrating B lymphocytes (TIL-Bs)) have a crucial, synergistic role in tumour control. In many cancers, TIL-Bs have demonstrated strong predictive and prognostic significance in the context of both standard treatments and immune checkpoint blockade, offering the prospect of new therapeutic opportunities that leverage their unique immunological properties. Drawing insights from autoimmunity, we review the molecular phenotypes, architectural contexts, antigen specificities, effector mechanisms and regulatory pathways relevant to TIL-Bs in human cancer.

View Article and Find Full Text PDF

PRAME is a prominent member of the cancer testis antigen family of proteins, which triggers autologous T cell-mediated immune responses. Integrative genomic analysis in diffuse large B cell lymphoma (DLBCL) uncovered recurrent and highly focal deletions of 22q11.22, including the PRAME gene, which were associated with poor outcome.

View Article and Find Full Text PDF

expansion conditions used to generate T cells for immunotherapy are thought to adopt metabolic phenotypes that impede therapeutic efficacy . The comparison of five different culture media used for clinical T cell expansion revealed unique optima based on different output variables, including proliferation, differentiation, function, activation, and mitochondrial phenotypes. The extent of proliferation and function depended on the culture media rather than stimulation conditions.

View Article and Find Full Text PDF

The life of RNA polymerase II (RNAPII) transcripts is shaped by the dynamic formation of mutually exclusive ribonucleoprotein complexes (RNPs) that direct transcript biogenesis and turnover. A key regulator of RNA metabolism in the nucleus is the scaffold protein ARS2 (arsenic resistance protein 2), bound to the cap binding complex (CBC). We report here that alternative splicing of ARS2's intron 5, generates cytoplasmic isoforms that lack 270 amino acids from the N-terminal of the protein and are functionally distinct from nuclear ARS2.

View Article and Find Full Text PDF

Poorly differentiated chordoma (PDC) is a recently recognized subtype of chordoma characterized by expression of the embryonic transcription factor, brachyury, and loss of INI1. PDC primarily affects children and is associated with a poor prognosis and limited treatment options. Here we describe the molecular and immune tumour microenvironment profiles of two paediatric PDCs produced using whole-genome, transcriptome and whole-genome bisulfite sequencing (WGBS) and multiplex immunohistochemistry.

View Article and Find Full Text PDF

ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an important tumour suppressor role, and is considered prognostic in several malignancies. However, in ovarian carcinomas there are contradictory reports on its relationship to outcome, immune response, and correlation with clinicopathological features. We assembled a series of 1623 endometriosis-associated ovarian carcinomas, including 1078 endometrioid (ENOC) and 545 clear cell (CCOC) ovarian carcinomas, through combining resources of the Ovarian Tumor Tissue Analysis (OTTA) Consortium, the Canadian Ovarian Unified Experimental Resource (COEUR), local, and collaborative networks.

View Article and Find Full Text PDF

The low mutational burden of epithelial ovarian cancer (EOC) is an impediment to immunotherapies that rely on conventional MHC-restricted, neoantigen-reactive T lymphocytes. Mucosa-associated invariant T (MAIT) cells are MR1-restricted T cells with remarkable immunomodulatory properties. We sought to characterize intratumoral and ascitic MAIT cells in EOC.

View Article and Find Full Text PDF

Background: There is suggestive evidence that inflammation is related to ovarian cancer survival. However, more research is needed to identify inflammation-related factors that are associated with ovarian cancer survival and to determine their combined effects.

Methods: This analysis used pooled data on 8,147 women with invasive epithelial ovarian cancer from the Ovarian Cancer Association Consortium.

View Article and Find Full Text PDF

Lymphocyte-rich classic Hodgkin lymphoma (LR-CHL) is a rare subtype of Hodgkin lymphoma. Recent technical advances have allowed for the characterization of specific cross-talk mechanisms between malignant Hodgkin Reed-Sternberg (HRS) cells and different normal immune cells in the tumor microenvironment (TME) of CHL. However, the TME of LR-CHL has not yet been characterized at single-cell resolution.

View Article and Find Full Text PDF

Avelumab in newly diagnosed glioblastoma.

Neurooncol Adv

August 2021

Clinique Neuro-Outaouais, Gatineau, Quebec, Canada.

Article Synopsis
  • Glioblastoma (GBM) employs immune suppression mechanisms like PD-L1 expression, and prior treatments targeting PD-1 didn’t show effectiveness; avelumab is a new PD-L1 targeting antibody capable of enhancing immune response.
  • A phase II study added avelumab (10 mg/kg IV every two weeks) to the standard treatment for newly diagnosed GBM, focusing on safety and evaluating progression-free survival (PFS) and overall survival (OS).
  • Out of 30 patients, 23.3% showed a positive response, with median PFS of 9.7 months and OS of 15.3 months, but the study revealed no new safety concerns or significant survival benefits from adding avelumab.
View Article and Find Full Text PDF

How Many Health Research Biobanks Are There?

Biopreserv Biobank

June 2022

Biobanking and Biospecimen Research Services, Deeley Research Centre, BC Cancer Victoria Center, Victoria, Canada.

Article Synopsis
  • Many stakeholders in research need to know how many biobanks exist, but this information is often hard to find through traditional data sources like institutions or research funders.
  • Recent advancements in online biobank locators from 12 countries have helped provide initial data on the number of health research biobanks relative to population size.
  • Analyzing four specific biobank locators reveals that there are about 11-30 biobanks for every million people in regions with high research capacity, and these locators can help optimize biobank utilization and reduce duplication in resources.
View Article and Find Full Text PDF

Analysis of Trends in Biospecimen Complexity in Cancer Research Over Two Decades.

Biopreserv Biobank

April 2022

Biobanking and Biospecimen Research Services, Deeley Research Centre, BC Cancer, Victoria, Canada.

Over time, researchers' demand for increased quality and quantity of biospecimens has risen. However, quality is multifaceted, ranging from simple to complex, and comes at a cost. Therefore, to be sustainable and ensure optimal utilization of their resources (supply), biobanks must consider the trends in biospecimen use to predict the needs for future biospecimen quality (demand).

View Article and Find Full Text PDF

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal cancers with a dismal 5-year survival rate of 5% and very limited efficacy of the current therapeutic regimens. The lethality of PDAC stems from asymptomatic early stage of the disease, its propensity to rapidly disseminate, as well as unusual, dense and highly active surrounding stroma. Fortunately, promising literature data suggests that exploiting newly contextualized type of cell death, termed "ferroptosis", has great potential for overcoming the major problems regarding PDAC treatment.

View Article and Find Full Text PDF

Raman spectroscopy is a non-invasive optical technique that can be used to investigate biochemical information embedded in cells and tissues exposed to ionizing radiation used in cancer therapy. Raman spectroscopy could potentially be incorporated in personalized radiation treatment design as a tool to monitor radiation response in at the metabolic level. However, tracking biochemical dynamics remains challenging for Raman spectroscopy.

View Article and Find Full Text PDF

Triple negative breast cancer holds a dismal clinical outcome and as such, patients routinely undergo aggressive, highly toxic treatment regimens. Clinical trials for TNBC employing immune checkpoint blockade in combination with chemotherapy show modest prognostic benefit, but the percentage of patients that respond to treatment is low, and patients often succumb to relapsed disease. Here, we show that a combination immunotherapy platform utilizing low dose chemotherapy (FEC) combined with oncolytic virotherapy (oHSV-1) increases tumor-infiltrating lymphocytes, in otherwise immune-bare tumors, allowing 60% of mice to achieve durable tumor regression when treated with immune checkpoint blockade.

View Article and Find Full Text PDF

Finding the Value in Biobanks: Enhancing the CTRNet Locator.

Biopreserv Biobank

April 2022

Office of Biobank Education and Research, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Biobanks are a critical piece of Research Infrastructure (RI). However, biobanks need to accept the reality of a life cycle for RIs. Until recently, strategies to sustain biobanks have been commonly focused on ways to maintain current operational models.

View Article and Find Full Text PDF

The microbiome of blood-sucking arthropods can shape their competence to acquire and maintain infections with vector-borne pathogens. We used a controlled study to investigate the interactions between Borrelia afzelii, which causes Lyme borreliosis in Europe, and the bacterial microbiome of Ixodes ricinus, its primary tick vector. We applied a surface sterilization treatment to eggs to produce dysbiosed tick larvae that had a low bacterial abundance and a changed bacterial microbiome compared to those of the control larvae.

View Article and Find Full Text PDF

Building Research Support Capacity across Human Health Biobanks during the COVID-19 Pandemic.

Biomark Insights

June 2021

New South Wales Health Statewide Biobank, New South Wales Health Pathology, Camperdown, NSW, Australia.

Human health biobanks are forms of research infrastructure that supply biospecimens and associated data to researchers, and therefore juxtapose the activities of clinical care and biomedical research. The discipline of biobanking has existed for over 20 years and is supported by several international professional societies and dedicated academic journals. However, despite both rising research demand for human biospecimens, and the growth of biobanking as an academic discipline, many individual biobanks continue to experience sustainability challenges.

View Article and Find Full Text PDF
Article Synopsis
  • Ticks called Ixodes ricinus can carry bacteria that cause diseases like Lyme disease, and they also have good bacteria that don't harm them.
  • Researchers studied how these bacteria affect ticks' growth and survival when the ticks fed on infected or uninfected mice.
  • The study found that while ticks feeding on infected mice grew a little faster, the overall impact of the bacteria on their growth and health wasn't big or important.
View Article and Find Full Text PDF